Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: James Cornwell who wrote (960)	5/30/1998 9:34:00 PM
From: greg Benfield	Respond to of 2887

My biggest dilemma is where I can free up some more cash. and which of my two babies I should buy more of. Decisions...Decisions. I don't think that is the real Dr. Summers. It is more likely to be Susan Summers. Where is Mr. Roper when you need him. Greg

To: James Cornwell who wrote (960)	5/31/1998 10:58:00 AM
From: Jeffrey L. Henken	Respond to of 2887

AMERICAN BIOMED RECEIVES US PATENT FOR GUIDEWIRE MICROFILTER PRODUCT The Woodlands, Texas, December 19, 1997 - American BioMed, Inc. (OTC Bulletin Board: ABMI),a manufacturer of minimally invasive medical devices for the treatment of cardiovascular disease, today announced the U.S. Patent and Trademark Office issued U.S. Patent 5695519 for the company's guidewire microfilter product, the OmniFilter. Originally filed on November 30, 1995, this is the first patent received for this product. The OmniFilter, a percutaneous guidewire microfilter that converts a standard guidewire into a temporary microemboli filter, is designed to prevent stroke-causing blood clots from reaching various organs of the body. Its patented "purse string" closure secures clot removal without loss into the blood stream, and its cost-effective design reduces the chance of stroke and prevents distal embolization. Industry analysts estimate a $500 million annual worldwide market for carotid angioplasty applications using this technology, with the U.S. representing approximately one-half of the worldwide market. The company has engaged Southwest Research Institute, an applied research and development organization, for the technical design/prototype development of the OmniFilter. The company anticipates initial prototypes will be available in the first quarter of 1998, with a product launch following in late 1998. Commenting on the announcement, American BioMed's Principal Clinical Investigator, Dr. Samuel S. Ahn, stated, "Surgeons and interventionalists need guidewire microfilter technology to prevent strokes that may occur during carotid balloon angioplasty procedures. American Biomed's OmniFilter may provide an important solution." Steven B. Rash, president and chief executive officer, stated, "Receipt of a patent for the company's OmniFilter product further validates its unique design and superior performance characteristics. It is our continued objective to develop proprietary technology to broaden American BioMed's existing product offering, as well as expand the company's visibility in the marketplace." American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally-invasive medical, surgical and diagnostic devices for the treatment of cardiovascular disease. The company's products include: 100% silicone-based catheters, through its Cathlab subsidiary; the Evert-O-Cath™, a toposcopic catheter for site-specific drug delivery and fluid removal; the OmniCathr, an atherectomy catheter designed to remove athersclerotic plaque from obstructed blood vessels throughout the body; the OmniStent™, which uses stent technology for angioplasty and atherectomy procedures; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The company has over twenty five patents covering its product portfolio, and the combined worldwide market is estimated at over $10 billion annually. It seems like companies always get a bit ahead of themselves when predicting when a product will reach market. You know something like Window's 95. The reason I reprinted this press release is that this is a very unique product with very large market potential and the prototype should be available soon. GO ABMI! Regards, Jeff